Neuland Laboratories Ltd

Neuland Laboratories announced that the 41th Annual General Meeting(AGM) of the company will be held on 30 July 2025.Powered by Capital Market - Live

On quarter on quarter (QoQ) basis, the company's net profit declined 72.63% while revenue fell 17.5% in Q4 FY25. Profit before tax (PBT) dropped 57.4% YoY to Rs 39.30 crore in Q4 FY25. During the quarter EBITDA stood at Rs 58.2 crore, registering de-growth of 48.1% compared with Rs 112.2 crore posted in the same quarter last year. EBITDA margin reduced 1,140 bps to 17.3% in Q4 FY25 as against 28.7% in Q4 FY24. Total expenses fell 0.55% to Rs 296.52 crore in Q4 FY25 as compared with Rs 298.16 crore in Q4 FY24. Cost of material consumed stood at Rs 141.24 crore (down 19.28% Yoy), employee benefit expenses were at Rs 66.45 crore (down 6.35% YoY), finance cost stood at Rs 2.34 crore (down 35% YoY), while manufacturing expenses stood at Rs 45.09 crore (up 3.09% YoY ) during the period under review. On full year basis, the company's consolidated net profit declined 13.3% to Rs 260.11 crore on 5.2% fall in revenue from operations to Rs 1,476.84 crore in FY25 over FY24. Sucheth Davuluri, vice-chairman and chief executive officer of the company said, 'We saw marginal decrease in topline in FY25 as compared to FY24, which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth.' Saharsh Davuluri, vice chairman and managing director, Neuland Laboratories added, 'The CMS revenues of Rs 637 crore were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26.' Meanwhile, the company's board recommended payment of final dividend of Rs 12 per share on a face value of Rs 10 each, for the financial year 2024-25. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 41st Annual General Meeting (AGM). The company has fixed the record date as 18 July 2025. The company's board has approved the convening of the 41st AGM of the shareholders on Wednesday, July 30, 2025. Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.Powered by Capital Market - Live

Net profit of Neuland Laboratories declined 58.84% to Rs 27.81 crore in the quarter ended March 2025 as against Rs 67.56 crore during the previous quarter ended March 2024. Sales declined 14.71% to Rs 328.36 crore in the quarter ended March 2025 as against Rs 385.01 crore during the previous quarter ended March 2024. For the full year,net profit declined 13.32% to Rs 260.11 crore in the year ended March 2025 as against Rs 300.08 crore during the previous year ended March 2024. Sales declined 5.24% to Rs 1476.84 crore in the year ended March 2025 as against Rs 1558.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales328.36385.01 -15 1476.841558.58 -5 OPM %15.5627.77 -21.8929.68 - PBDT56.19108.66 -48 335.48461.14 -27 PBT39.3092.20 -57 269.93401.44 -33 NP27.8167.56 -59 260.11300.08 -13 Powered by Capital Market - Live

Neuland Laboratories announced that the Board of Directors of the Company at its meeting held on 15 May 2025, has recommended a Final Dividend of Rs.12 per share (i.e.120%), subject to the approval of the shareholders.Powered by Capital Market - Live

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live

Neuland Laboratories Ltd gained 2.02% today to trade at Rs 13000. The BSE Healthcare index is up 0.35% to quote at 41465.13. The index is up 2.44 % over last one month. Among the other constituents of the index, Wockhardt Ltd increased 1.79% and Narayana Hrudayalaya Ltd added 1.75% on the day. The BSE Healthcare index went up 18.45 % over last one year compared to the 5.39% surge in benchmark SENSEX. Neuland Laboratories Ltd has added 14.87% over last one month compared to 2.44% gain in BSE Healthcare index and 2.09% rise in the SENSEX. On the BSE, 29 shares were traded in the counter so far compared with average daily volumes of 2530 shares in the past one month. The stock hit a record high of Rs 18089.55 on 04 Dec 2024. The stock hit a 52-week low of Rs 5557 on 04 Jun 2024.Powered by Capital Market - Live

Neuland Laboratories announced that Parag Deshmukh has been appointed as Head - Manufacturing w.e.f. 10 March 2025.Powered by Capital Market - Live

Neuland Laboratories announced that India Ratings and Research has affirmed the credit rating assigned to the Company as under: Long term - IND A+/Positive Fund-Based Limits - IND A+/Positive / IND A1 Non-Fund Based limits - IND A1 Powered by Capital Market - Live

Vesuvius India Ltd, Pfizer Ltd, Data Patterns (India) Ltd and Orchid Pharma Ltd are among the other gainers in the BSE's 'A' group today, 24 February 2025.Neuland Laboratories Ltd spiked 10.62% to Rs 12164.7 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 2963 shares were traded on the counter so far as against the average daily volumes of 1843 shares in the past one month. Vesuvius India Ltd surged 6.76% to Rs 4084.95. The stock was the second biggest gainer in 'A' group. On the BSE, 1309 shares were traded on the counter so far as against the average daily volumes of 767 shares in the past one month. Pfizer Ltd soared 6.02% to Rs 4340.95. The stock was the third biggest gainer in 'A' group. On the BSE, 16599 shares were traded on the counter so far as against the average daily volumes of 1684 shares in the past one month. Data Patterns (India) Ltd advanced 5.76% to Rs 1643.65. The stock was the fourth biggest gainer in 'A' group. On the BSE, 40437 shares were traded on the counter so far as against the average daily volumes of 29406 shares in the past one month. Orchid Pharma Ltd jumped 5.00% to Rs 966.15. The stock was the fifth biggest gainer in 'A' group. On the BSE, 9903 shares were traded on the counter so far as against the average daily volumes of 13157 shares in the past one month. Powered by Capital Market - Live

Neuland Laboratories Ltd lost 3.78% today to trade at Rs 13142.7. The BSE Healthcare index is down 0.71% to quote at 40715.74. The index is down 4.34 % over last one month. Among the other constituents of the index, Wockhardt Ltd decreased 3.51% and Sequent Scientific Ltd lost 3.22% on the day. The BSE Healthcare index went up 15.34 % over last one year compared to the 6.43% surge in benchmark SENSEX. Neuland Laboratories Ltd has added 0.38% over last one month compared to 4.34% fall in BSE Healthcare index and 0.23% drop in the SENSEX. On the BSE, 65 shares were traded in the counter so far compared with average daily volumes of 1407 shares in the past one month. The stock hit a record high of Rs 18089.55 on 04 Dec 2024. The stock hit a 52-week low of Rs 5532.5 on 14 Mar 2024.Powered by Capital Market - Live